Acumen announces new research at CTAD on ACU193

Acumen (ABOS) Pharmaceuticals announced new research at the 18th Annual Clinical Trials on Alzheimer’s Disease, CTAD, conference, taking place December 1-4, 2025, in San Diego and online. Results from a collaborative study with JCR Pharmaceuticals demonstrated improved delivery of AbetaO-targeting monoclonal antibodies to the central nervous system, including sabirnetug, ACU193, through the blood-brain barrier using the transferrin receptor pathway, which is being developed to potentially increase and broaden brain distribution and maximize the efficacy-to-safety ratio. Building on these results, Acumen and JCR Pharmaceuticals are now developing TfR-targeting antibodies for clinical testing. Additionally, results on clinical trial recruitment from the Phase 2 ALTITUDE-AD clinical trial showed that site databases and physician referrals were the most reliable recruitment methods overall.